CSO of S-TARget therapeutics GmbH and OncoQR ML OG

Dr. Geert C. Mudde received a Ph.D. in immunology from the University of Utrecht in 1985 and started his international professional career at the Swiss Institute for Asthma and Allergy Research in Davos in 1989. In 1992 he joined the pharmaceutical/biotech industry, where he held several senior management positions such as “Deputy Head of the Immunology Department” at the Novartis Research Institute in Vienna, Austria, “Director of Allergy and Inflammation/Immunology” at the Parke Davis Research Institute in Fresnes, France, “Director Immunology” at Ingenium Pharmaceuticals, Martinsried, Germany, and “VP Exploratory Research” at igeneon AG, Vienna, Austria. Finally, in 2006, while joining Baxter BioScience in Vienna as interim “Director Discovery Research”. Dr. Mudde (co-)founded f-star GmbH in 2006 and is founder and serves as CSO of S-TARget therapeutics GmbH (2009) as well as OncoQR ML OG which was founded in 2013.

Persönliches Profil

CSO and Founder at OncoQR ML, S-TARget therapeutics GmbH and TYG oncology Ltd.